Cellulosic-Coated Potassium Chloride for Consistent Sustained Release

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing potassium chloride formulations struggle with inefficient sustained release profiles, high production costs, and inconsistent dosing accuracy, particularly in formulations for treating potassium deficiency.

Innovation Solution

A sustained release pharmaceutical composition comprising Potassium chloride crystals with a mesh size of 60 to 100 mesh coated with up to 9% cellulosic polymers, combined with pharmaceutically acceptable excipients, to achieve improved dissolution profiles and bioavailability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If conventional potassium chloride formulations (tablets or capsules) are used, then convenience and ease of administration are improved, but sustained release profile and dissolution control are insufficient

Engineering Contradiction:
Improveease of administrationVSAvoidsustained release profile
Core Design Contradiction:
Ease of operationVSDuration of action of moving object

Solution Approach 1:

The potassium chloride crystals are pre-coated with cellulosic polymer before formulation into tablets or capsules. This preliminary coating action ensures that the sustained release mechanism is established before administration, allowing the convenient tablet/capsule form to deliver controlled release over time without requiring additional patient actions.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention changes the physical-chemical parameters of the potassium chloride formulation by using fine mesh size crystals (60-100 mesh) and coating them with a specific amount of cellulosic polymer (up to 9% w/w). These parameter changes transform the conventional immediate-release formulation into a sustained-release formulation while maintaining tablet or capsule dosage forms for ease of administration.

Inventive Principle:
Principle #35Parameter changes

2Duration of action of moving object

If existing controlled release formulations are used, then sustained release is achieved, but production cost and manufacturing complexity increase

Engineering Contradiction:
Improvesustained releaseVSAvoidproduction cost
Core Design Contradiction:
Duration of action of moving objectVSEase of manufacture

Solution Approach 1:

The invention optimizes manufacturing parameters by using fine mesh potassium chloride crystals (60-100 mesh) that require less polymer coating (up to 9% w/w) to achieve sustained release. This parameter optimization reduces material costs and simplifies the coating process compared to conventional formulations that require higher polymer amounts and more complex processing.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The use of fine mesh crystals (60-100 mesh) creates a porous structure that enhances polymer penetration and binding efficiency. This porous structure allows for more effective sustained release with lower polymer content, reducing manufacturing costs while maintaining the sustained release profile.

Inventive Principle:
Principle #31Porous materials

3Quantity of substance

If existing formulations are used, then potassium supplementation is provided, but dissolution profile consistency and bioavailability are insufficient

Engineering Contradiction:
Improvepotassium supplementationVSAvoiddissolution profile consistency
Core Design Contradiction:
Quantity of substanceVSManufacturing precision

Solution Approach 1:

The invention applies local quality control by coating each potassium chloride crystal individually with cellulosic polymer. This ensures uniform drug release characteristics across all crystals in the formulation, leading to consistent dissolution profiles and reliable bioavailability. The fine mesh size (60-100 mesh) ensures uniform coating coverage on each particle.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

By changing the crystal size parameter to fine mesh (60-100 mesh) and controlling the polymer coating amount (up to 9% w/w), the invention achieves optimal dissolution characteristics. These parameter changes ensure consistent drug release rates and improve bioavailability compared to conventional formulations with larger, less uniformly coated crystals.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition ensures sustained drug release, enhanced bioavailability, high content uniformity, and cost-effective, efficient manufacturing, facilitating large-scale production.

Implementation Method 1

the potassium chloride crystals are coated with a coating solution comprising cellulosic polymer... exhibits an advantageous dissolution profile

Methodology Applied
Scientific EffectDissolution: Solvation

Data Source

PatentUS20260041642A1Sustained Release Pharmaceutical Composition Comprising Potassium Chloride
Publication Date: 2026.02.12 GRANULES INDIA LIMITED

AI summary

The present invention relates to sustained release formulations of Potassium chloride crystals having a mesh size ranging from about 60 to 100 mesh, combined with one or more pharmaceutically acceptable excipients, wherein the potassium chloride crystals are coated with a coating solution comprising cellulosic polymer in an amount up to 9% w/w based on the total weight of the granules and to processes for their preparation.